CSTL — Stock Film
STOCK FILMSCENE 1/11CSTL · $23.72
Stock Expert AI presents
CSTL
Castle Biosciences, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Castle Biosciences, Inc. A quick introduction.

On the stock market since 2019, it operates in the world of health and science. It has 942 employees. Now — the numbers.

on the stock market since 2019
942 employees
$719.4M market value
Revenue last year:
$0
The loss that same year:
$0
For every $1 it earns, the company spends $1.1.

The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.

THE SALES TREND
Sales are growing, year after year.

Average growth of 38% a year over the last 4 years. Red columns mark years that ended in a loss.

$94.1M
2021
$137M
2022
$219.8M
2023
$332.1M
2024
$344.2M
2025
In the vault right now:
$0
DEBT: $36.9M
At this pace, that money lasts about 12.4 years.

Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
81
very strong

Profit power and business quality lead the class.

FINANCIAL STRENGTH
29
very weak

Clearly below the class average.

VALUATION
67
strong

Clearly above the class average — a step short of the very top.

GROWTH
20
very weak

Clearly below the class average.

PRICE MOMENTUM
39
weak

Clearly below the class average.

WORTH WATCHING

Growth: Sales growth trails the sector average.

Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 5 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Fat profit per sale, but shrinking10/10
A strong cash pile8/10
Few are betting against it10/10
WEAK SPOTS
The stock has lost its spark0/10
Executives aren’t buying3/10
WORTH WATCHING

Executive Buying: The trades send no strong signal of confidence.

THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 69% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/3
The product is selling

Sales run at $344.2M a year. A small number, but proof the product has real buyers.

2
THE BRIGHT SIDE · 2/3
Strong cash, light debt

There is $299.5M in the vault; even if every debt were paid off, $262.6M would remain.

3
THE BRIGHT SIDE · 3/3
Delivers on expectations

It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.

1
THE RISKS · 1/3
Running at a loss

A loss of $24.2M against $344.2M in annual sales.

2
THE RISKS · 2/3
Growth trails the sector

The growth engine is running at low revs right now. Report-card grade: 20/100.

3
THE RISKS · 3/3
A thin financial cushion

The balance sheet offers little cushion against a rough stretch. Report-card grade: 29/100.

FINALE · THE GRADE
F
0 / 100 · MoonshotScore

On our five-subject report card, CSTL sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: CSTL is a high-risk stock — not yet profitable, and its future rides on its product catching on.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Jul 21, 2026 · stockexpertai.com · Stock Film